Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie
This study is a double blind, randomized, investigator initiated study on glucose-lowering effects and Safety of Adding 0.25 or 0.5 mg Duvie (Lobeglitazone) in Patients With Type 2 Diabetes With Inadequate Control on Metformin and DPP-4 Inhibitor Therapy. The primary aim of the study is to compared changes of HbA1c between 0.25mg robeblitazone add-on group and 0.5mg robeglitazone add-on group.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
159
take the intervention drug once daily according to the randomized groups
Pusan National University Hospital
Busan, South Korea
HbA1c at 24 week
changes of HbA1c between baseline and 24 week
Time frame: 24 week
HOMA-IR
changes of HOMA-IR between baseline and 24 week
Time frame: 24 week
lipid levels
changes of lipid levels between baseline and 24 week
Time frame: 24 week
hs-CRP
changes of hs-CRP between baseline and 24 week
Time frame: 24 week
AST
changes of AST between baseline and 24 week
Time frame: 24 week
adiponectin
changes of adiponectin between baseline and 24 week
Time frame: 24 week
adverse event (weight gain,edema)
changes of adverse event (weight gain,edema) between baseline and 24 week
Time frame: 24 week
ALT
changes of ALT between baseline and 24 week
Time frame: 24 week
ALP
changes of ALP between baseline and 24 week
Time frame: 24 week
total bilirubin
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
changes of total bilirubin between baseline and 24 week
Time frame: 24 week